NightHawk Biosciences Inc (NHWK)

[dia76ca]

On the ratings front, Griffin analyst Keith Markey initiated coverage with a Buy rating on HTBX and a price target of $2.25, in a report issued on September 12. The current price target represents a potential upside of 302% from where the stock is currently trading.
To back his bullish call, the analyst wrote, “Heat Biologics has developed a T cell activation platform (TCAP) to initiate or enhance an immune attack against solid tumors. The therapy utilizes an off-the-shelf approach to present a large number of tumor-associated antigens in vivo to drive an immune response. The two central elements of the ImPACT platform are cancer cell lines that are representative of the tumor being treated and a fusion protein consisting of the heat shock protein gp96 and the secretory, constant portion (Fc) of the immune globulin G. Heat is developing a third element for inclusion in its second-generation ComPACT platform. The new addition is a costimulatory agonist that has the ability to augment the initial T cell activation and thereafter favor memory T-cell formation. This therapy has the potential to promote a durable immune response and clinical benefit, notably in two groups that account for most cancer cases, the elderly and individuals with compromised immune systems. As such, we view the Company’s immunotherapies to be far more sophisticated than “vaccines” that also use an antigen-based approach to stimulate the immune system.”